24M people suffer from diabetes in the US, and over 200M are afflicted internationally. Costs to the US healthcare system alone are running at a rate of over $170B per year and rising. There has been no fundamental breakthrough in diabetes therapy since the discovery of insulin in 1921, with currently available palliatives that lower blood sugar levels for a limited time being the only treatment available.

exsulin is focused on development of a therapy to regenerate insulin producing islets in T1DM & T2DM. This represents a breakthrough in the underlying cause of diabetes – a loss of insulin-producing islets. exsulin is focused on development for the high unmet clinical need of diabetes patients. Current studies are targeted at T1DM patients – the first potential breakthrough for over 80 years --- since the discovery of insulin. T2DM studies will follow.


Risks and Cost of Diabetes in the North America

Approximately 1.5 million new cases of diabetes are diagnosed annually in people aged 20 years or older. Roughly 8% of all Americans today have diabetes.

The number of North Americans with diabetes more than doubled in the past 15 years and continues to escalate as a major public health threat.

Complications of diabetes include heart disease, blindness, kidney disease, nervous system disease, neuropathy, amputations and more.

Total cost of diabetes in the U.S is estimated at $174 billion in 2007 with direct medical costs estimated at $116 billion (NIH)

There were 24.3 million diabetes-related hospitalization days in 2007 at an average cost of $2,000 per day (American Diabetes Association)

The risk for complications and sudden death among people with diabetes is more than double that of people without diabetes.  

For more information on the risk and cost of diabetes:

American Diabetes Association

National Diabetes Fact Sheet

The Economic Burden of Diabetes (2010 Jan 14)